Are ERBB2 mutations a 'ready for routine use' target in patients with metastatic breast cancer?
ESMO Open
.
2023 Oct;8(5):101832.
doi: 10.1016/j.esmoop.2023.101832.
Epub 2023 Sep 26.
Authors
T Grinda
1
,
B Pistilli
2
Affiliations
1
Department of Medical Oncology, Gustave Roussy, Villejuif, France.
2
Department of Medical Oncology, Gustave Roussy, Villejuif, France. Electronic address:
[email protected]
.
PMID:
37769401
PMCID:
PMC10539925
DOI:
10.1016/j.esmoop.2023.101832
No abstract available
Publication types
Editorial